Acurx's Novel DNA Pol IIIC Inhibitors Show Promise for Antibiotic Development

Acurx Pharmaceuticals' Scientific Presentation at ESCMID Global 2026

Acurx Pharmaceuticals, Inc. has made significant strides in the fight against antibiotic-resistant infections with its recent findings on DNA pol IIIC inhibitors. On May 4, 2026, at the 35th Congress of ESCMID Global held in Munich, Germany, the company showcased a compelling scientific poster titled Preclinical Microbiome Evaluation of Novel PolC-Inhibitor Compounds. The research, presented by Dr. Khurshida Begum from the University of Houston College of Pharmacy, outlines how these inhibitors demonstrate an unexpected benefit of preserving gut microbiome integrity while displaying strong antibacterial properties against systemic infections.

Background

Antibiotic resistance is a pressing medical challenge, especially cases caused by methicillin-resistant Staphylococcus aureus (MRSA). Traditional antibiotics often disrupt gut microbiota, leading to complications such as antibiotic-associated diarrhea or Clostridioides difficile infections. Acurx's DNA pol IIIC inhibitors are designed as a targeted solution that could change the landscape of antibiotic therapy.

Study Findings

In the study involving neutropenic CD-1 mice, subjects were infected intramuscularly with MRSA and were subsequently treated with either one of three Acurx DNA pol IIIC inhibitors, linezolid, or a placebo. Remarkably, Acurx’s compounds not only achieved therapeutic plasma levels but also resulted in a reduced tissue burden of MRSA. Even more encouraging was the finding that these antibiotics maintained a markedly higher diversity of gut microbes compared to those treated with linezolid, thereby preserving a healthier microbial environment.

The results illustrate that Acurx’s DNA pol IIIC compounds effectively supported a Bacteroidota-dominant microbiome and prevented the overgrowth of Proteobacteria, which are often associated with dysbiosis—a harmful disruption of gut flora. These inhibitors represent a class effect that maintains gut microbiome structure while combating serious bacterial threats, marking a significant advancement in antibacterial therapy.

Expert Opinions

Prominent figures in microbiology highlighted the importance of these findings. Kevin Garey, PharmD, and Robert L. Boblitt emphasized the breakthrough nature of selectively targeting harmful pathogens while safeguarding beneficial gut bacteria. The preservation of the microbiome while treating systemic infections represents a vital breakthrough that could reshape clinical practices in antibiotic prescription.

Future Implications

Robert J. DeLuccia, Acurx's Executive Chairman, noted that this discovery could be revolutionary for treating severe Gram-positive infections, effectively addressing a paradox in treatment strategies. The findings from ESCMID suggest that Acurx’s approach might reduce the risk of complications related to antibiotic use, including gut dysbiosis.

Furthermore, Acurx is set to expand its research efforts through collaboration with institutes like Leiden University Medical Center, aiming to refine and develop new DNA pol IIIC inhibitors based on these findings. Their ongoing studies look promising within their portfolio, targeting serious infections while also considering regulatory pathways for further clinical development.

Conclusion

Acurx Pharmaceuticals is at the forefront of innovative solutions in antibiotic development, addressing a critical need as antibiotic resistance continues to escalate. The findings presented at ESCMID highlight the potential of DNA pol IIIC inhibitors as not just effective antibacterial agents but also as crucial players in preserving gut health, which is integral to overall well-being. With ongoing research and development, Acurx is poised to make significant contributions to modern medicine, potentially altering treatment protocols for resistant bacterial infections.

For more information about Acurx Pharmaceuticals and its promising pipeline, visit Acurx Pharmaceuticals.